In this insightful discussion, Peter Loftus, a reporter with the Wall Street Journal, unpacks the surprising ousting of Novo Nordisk's CEO, Lars Jorgensen, amid Ozempic's skyrocketing success. He explores the unique nonprofit structure of Novo Nordisk and how it affects corporate governance. The conversation also delves into the fierce rivalry with Eli Lilly, revealing how the market landscape for anti-obesity drugs has evolved, and the implications of recent clinical trial setbacks on investor confidence.
